Q2 2026 saw strong organic growth, higher profitability, and robust free cash flow, led by double-digit gains in Prosthetics & Neuro Orthotics and solid performance in EMEA and APAC. Patient Care faced headwinds in Europe but improved in the Americas. Full-year guidance was narrowed, with expectations for a stronger H2 and continued margin discipline.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.